MWF/ZtmRrrc |
renal filtration fraction |
control condition |
Remuzzi A, et al., J Clin Invest. 1990 Feb;85(2):541-9. |
glomerular filtration trait |
male |
126 days
| 7 |
0.19 |
null |
0.02 |
0.06 |
p-aminohippurate analysis by liquid phase colorimetry |
0.0 |
0 |
100943 |
2541 |
MWF/ZtmRrrc |
renal plasma flow to body weight ratio |
control condition |
Remuzzi A, et al., J Clin Invest. 1990 Feb;85(2):541-9. |
kidney plasma flow trait |
male |
126 days
| 7 |
2.44 |
ml/min/100g |
0.28 |
0.73 |
p-aminohippurate analysis by liquid phase colorimetry |
0.0 |
0 |
100939 |
2541 |
MWF/ZtmRrrc |
renal plasma flow (PAH) |
enalapril (50 mg/l) (for 182 days) |
Remuzzi A, et al., J Clin Invest. 1990 Feb;85(2):541-9. |
kidney plasma flow trait |
male |
246 days
| 6 |
7.6 |
ml/min |
0.33 |
0.8 |
p-aminohippurate analysis by liquid phase colorimetry |
0.0 |
0 |
100938 |
2541 |
MWF/ZtmRrrc |
renal filtration fraction |
enalapril (50 mg/l) (for 182 days) |
Remuzzi A, et al., J Clin Invest. 1990 Feb;85(2):541-9. |
glomerular filtration trait |
male |
246 days
| 6 |
0.3 |
null |
0.02 |
0.04 |
p-aminohippurate analysis by liquid phase colorimetry |
0.0 |
0 |
100946 |
2541 |
MWF/ZtmRrrc |
renal plasma flow to body weight ratio |
control condition |
Remuzzi A, et al., J Clin Invest. 1990 Feb;85(2):541-9. |
kidney plasma flow trait |
male |
246 days
| 8 |
1.72 |
ml/min/100g |
0.07 |
0.19 |
p-aminohippurate analysis by liquid phase colorimetry |
0.0 |
0 |
100941 |
2541 |
MWF/ZtmRrrc |
renal plasma flow to body weight ratio |
enalapril (50 mg/l) (for 182 days) |
Remuzzi A, et al., J Clin Invest. 1990 Feb;85(2):541-9. |
kidney plasma flow trait |
male |
246 days
| 6 |
1.71 |
ml/min/100g |
0.09 |
0.23 |
p-aminohippurate analysis by liquid phase colorimetry |
0.0 |
0 |
100942 |
2541 |
MWF/ZtmRrrc |
renal plasma flow (PAH) |
enalapril (50 mg/l) (for 60 days) |
Remuzzi A, et al., J Clin Invest. 1990 Feb;85(2):541-9. |
kidney plasma flow trait |
male |
126 days
| 8 |
10.6 |
ml/min |
0.57 |
1.6 |
p-aminohippurate analysis by liquid phase colorimetry |
0.0 |
0 |
100936 |
2541 |
MWF/ZtmRrrc |
renal filtration fraction |
control condition |
Remuzzi A, et al., J Clin Invest. 1990 Feb;85(2):541-9. |
glomerular filtration trait |
male |
246 days
| 8 |
0.27 |
null |
0.01 |
0.04 |
p-aminohippurate analysis by liquid phase colorimetry |
0.0 |
0 |
100945 |
2541 |
MWF/ZtmRrrc |
renal plasma flow (PAH) |
control condition |
Remuzzi A, et al., J Clin Invest. 1990 Feb;85(2):541-9. |
kidney plasma flow trait |
male |
126 days
| 7 |
9.4 |
ml/min |
1.02 |
2.7 |
p-aminohippurate analysis by liquid phase colorimetry |
0.0 |
0 |
100935 |
2541 |
MWF/ZtmRrrc |
renal plasma flow (PAH) |
control condition |
Remuzzi A, et al., J Clin Invest. 1990 Feb;85(2):541-9. |
kidney plasma flow trait |
male |
246 days
| 8 |
7.4 |
ml/min |
0.28 |
0.8 |
p-aminohippurate analysis by liquid phase colorimetry |
0.0 |
0 |
100937 |
2541 |
MWF/ZtmRrrc |
renal plasma flow to body weight ratio |
enalapril (50 mg/l) (for 60 days) |
Remuzzi A, et al., J Clin Invest. 1990 Feb;85(2):541-9. |
kidney plasma flow trait |
male |
126 days
| 8 |
2.84 |
ml/min/100g |
0.14 |
0.39 |
p-aminohippurate analysis by liquid phase colorimetry |
0.0 |
0 |
100940 |
2541 |
MWF/ZtmRrrc |
renal filtration fraction |
enalapril (50 mg/l) (for 60 days) |
Remuzzi A, et al., J Clin Invest. 1990 Feb;85(2):541-9. |
glomerular filtration trait |
male |
126 days
| 8 |
0.21 |
null |
0.02 |
0.06 |
p-aminohippurate analysis by liquid phase colorimetry |
0.0 |
0 |
100944 |
2541 |